BioTech Companies Under SEC Scrutiny

Reuters reports:

"Biotechnology companies are under U.S. regulatory scrutiny over their disclosure of information about drugs under development, people familiar with the matter said on Monday.

Inquiries by the Securities and Exchange Commission have not risen to the level of an industry-wide probe, but the sources said a handful of investigations are under way."